The impact of immune system in regulating bone metastasis formation by osteotropic tumors

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  D'Amico, Lucia ^a   Roato, Ilaria ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

BONE CELL; BONE MARROW CELL; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CIRCULATING TUMOR CELL; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; MOLECULAR INTERACTION; NONHUMAN; PATHOGENESIS; REVIEW; SOLID TUMOR; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; BONE; BONE TUMOR; IMMUNOLOGY; NEOPLASM; PATHOLOGY;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; CYTOKINES; HUMANS; IMMUNE SYSTEM; NEOPLASMS;

EID: 84929629261     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/143526     Document Type: Review

References (92)

1. R. E. Coleman, "Clinical features of metastatic bone disease and risk of skeletal morbidity, " Clinical Cancer Research, vol. 12, part 2, pp. 6243s-6249s, 2006.
2. N. Sethi and Y. Kang, "Dysregulation of developmental pathways in bone metastasis, " Bone, vol. 48, no. 1, pp. 16-22, 2011.
3. G. R. Mundy, "Metastasis to bone: causes, consequences and therapeutic opportunities, " Nature Reviews Cancer, vol. 2, no. 8, pp. 584-593, 2002.
4. G. D. Roodman, "Mechanisms of bone metastasis, " The New England Journal of Medicine, vol. 350, no. 16, pp. 1655-1664, 2004.
5. R. E. Coleman, "Metastatic bone disease: clinical features, pathophysiology and treatment strategies, " Cancer Treatment Reviews, vol. 27, no. 3, pp. 165-176, 2001.
6. A. Lipton, "Bisphosphonates and breast carcinoma: present and future, " Cancer, vol. 88, no. 12, pp. 3033-3037, 2000.
7. R. E. Coleman, "Bisphosphonates: clinical experience, " Oncologist, vol. 9, supplement 4, pp. 14-27, 2004.
8. S. L. Wood and J. E. Brown, "Skeletal metastasis in renal cell carcinoma: current and future management options, " Cancer Treatment Reviews, vol. 38, no. 4, pp. 284-291, 2012.
9. M. R. Smith, "Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence, " Cancer Treatment Reviews, vol. 31, supplement 3, pp. 19-25, 2005.
10. L. M. Cook, G. Shay, A. Aruajo, and C. C. Lynch, "Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases, " Cancer andMetastasis Reviews, vol. 33, no. 2-3, pp. 511-525, 2014.
11. S. Azizidoost, S. Babashah, F. Rahim, M. Shahjahani, and N. Saki, "Bone marrow neoplastic niche in leukemia, " Hematology, vol. 19, no. 4, pp. 232-238, 2014.
12. O. Kollet, A. Dar, S. Shivtiel et al., "Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells, " Nature Medicine, vol. 12, no. 6, pp. 657-664, 2006.
13. L. M. Calvi, G. B. Adams, K. W. Weibrecht et al., "Osteoblastic cells regulate the haematopoietic stem cell niche, " Nature, vol. 425, no. 6960, pp. 841-846, 2003.
14. J. Zhang, C. Niu, L. Ye et al., "Identification of the haematopoietic stem cell niche and control of the niche size, " Nature, vol. 425, no. 6960, pp. 836-841, 2003.
15. S. I. Park, C. Lee, W.David Sadler et al., "Parathyroid hormonerelated protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth, " Cancer Research, vol. 73, no. 22, pp. 6574-6583, 2013.
16. Y. Shiozawa, E. A. Pedersen, A. M. Havens et al., "Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow, " The Journal of Clinical Investigation, vol. 121, no. 4, pp. 1298-1312, 2011.
17. J. E. Compston, "Bone marrow and bone: a functional unit, " Journal of Endocrinology, vol. 173, no. 3, pp. 387-394, 2002.
18. M. K. Herroon, E. Rajagurubandara, A. L. Hardaway et al., "Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms, " Oncotarget, vol. 4, no. 11, pp. 2108-2123, 2013.
19. B. F. Boyce, E. Rosenberg, A. E. de Papp, and L. T. Duong, "The osteoclast, bone remodelling and treatment of metabolic bone disease, " European Journal of Clinical Investigation, vol. 42, no. 12, pp. 1332-1341, 2012.
20. L. J. Suva, C. Washam, R. W. Nicholas, and R. J. Griffin, "Bone metastasis: mechanisms and therapeutic opportunities, " Nature Reviews Endocrinology, vol. 7, no. 4, pp. 208-218, 2011.
21. A. C. Chiang and J. Massagué, "Molecular basis of metastasis, " The New England Journal ofMedicine, vol. 359, no. 26, pp. 2814-2823, 2008.
22. X. Lu, E. Mu, Y. Wei et al., "VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors, " Cancer Cell, vol. 20, no. 6, pp. 701-714, 2011.
23. I. Pécheur, O. Peyruchaud, C.-M. Serre et al., "Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone, " The FASEB Journal, vol. 16, no. 10, pp. 1266-1268, 2002.
24. J. M. Reuben, B.-N. Lee, H. Gao et al., "Primary breast cancer patients with high risk clinicopathologic features have high percentages of bonemarrow epithelial cells with ALDH activity and CD44+CD24 cancer stem cell phenotype, " European Journal of Cancer, vol. 47, no. 10, pp. 1527-1536, 2011.
25. S. A. Patel, S. H. Ramkissoon, M. Bryan et al., "Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy, " Scientific Reports, vol. 2, article 906, 2012.
26. L. D'Amico, S. Patanè, C. Grange et al., "Primary breast cancer stem-like cells metastasise to bone, switch phenotype and acquire a bone tropism signature, " British Journal of Cancer, vol. 108, no. 12, pp. 2525-2536, 2013.
27. M. K. Conley-LaComb, A. Saliganan, P. Kandagatla, Y. Q. Chen, M. L. Cher, and S. R. Chinni, "PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling, " Molecular Cancer, vol. 12, no. 1, article 85, 2013.
28. R. S. Taichman, C. Cooper, E. T. Keller, K. J. Pienta, N. S. Taichman, and L. K.McCauley, "Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone, " Cancer Research, vol. 62, no. 6, pp. 1832-1837, 2002.
29. P. V. Hauschka, A. E. Mavrakos, M. D. Iafrati, S. E. Doleman, andM. Klagsbrun, "Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-sepharose, " The Journal of Biological Chemistry, vol. 261, no. 27, pp. 12665-12674, 1986.
30. A. Bellahcène, M.-P. Merville, and V. Castronovo, "Expression of bone sialoprotein, a bone matrix protein, in human breast cancer, " Cancer Research, vol. 54, no. 11, pp. 2823-2826, 1994.
31. A. Bellahcene and V. Castronovo, "Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer, " The American Journal of Pathology, vol. 146, no. 1, pp. 95-100, 1995.
32. K. S. Koeneman, F. Yeung, and L. W. Chung, "Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment, " Prostate, vol. 39, no. 4, pp. 246-261, 1999.
33. D.-L. Lin, C. P. Tarnowski, J. Zhang et al., "Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro, " The Prostate, vol. 47, no. 3, pp. 212-221, 2001.
34. R. F. Cox, A. Jenkinson, K. Pohl, F. J.O'Brien, and M. P.Morgan, "Osteomimicry of mammary adenocarcinoma cells in vitro; increased expression of bone matrix proteins and proliferation within a 3D collagen environment, " PLoS ONE, vol. 7, no. 7, Article ID e41679, 2012.
35. S. Chiba, "Notch signaling in stem cell systems, " Stem Cells, vol. 24, no. 11, pp. 2437-2447, 2006.
36. S. Santagata, F.Demichelis, A. Riva et al., "JAGGED1 expression is associated with prostate cancer metastasis and recurrence, " Cancer Research, vol. 64, no. 19, pp. 6854-6857, 2004.
37. N. Sethi, X. Dai, C. G. Winter, and Y. Kang, "Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells, " Cancer Cell, vol. 19, no. 2, pp. 192-205, 2011.
38. H. L. Aguila and D. W. Rowe, "Skeletal development, bone remodeling, and hematopoiesis, " Immunological Reviews, vol. 208, pp. 7-18, 2005.
39. H. Takayanagi, "New developments in osteoimmunology, " Nature Reviews Rheumatology, vol. 8, no. 11, pp. 684-689, 2012.
40. S. Kasagi and W. Chen, "TGF-beta1 on osteoimmunology and the bone component cells, " Cell and Bioscience, vol. 3, article 4, 2013.
41. F. Arai, A. Hirao, M. Ohmura et al., "Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche, " Cell, vol. 118, no. 2, pp. 149-161, 2004.
42. J. Zhu, R. Garrett, Y. Jung et al., "Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells, " Blood, vol. 109, no. 9, pp. 3706-3712, 2007.
43. P. J. Kostenuik and V. Shalhoub, "Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption, " Current Pharmaceutical Design, vol. 7, no. 8, pp. 613-635, 2001.
44. L. C. Hofbauer, C. A. Kühne, and V. Viereck, "The OPG/RANKL/RANK system in metabolic bone diseases, " Journal of Musculoskeletal Neuronal Interactions, vol. 4, no. 3, pp. 268-275, 2004.
45. B. R.Wong, R. Josien, S. Y. Lee et al., "TRANCE (Tumor necrosis factor [TNF]-related Activation-induced Cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor, " The Journal of Experimental Medicine, vol. 186, no. 12, pp. 2075-2080, 1997.
46. D. M. Anderson, E. Maraskovsky, W. L. Billingsley et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, " Nature, vol. 390, no. 6656, pp. 175-179, 1997.
47. Y.-Y. Kong, H. Yoshida, I. Sarosi et al., "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis, " Nature, vol. 397, no. 6717, pp. 315-323, 1999.
48. D. Santini, G. Perrone, I. Roato et al., "Expression pattern of receptor activator of NFB (RANK) in a series of primary solid tumors and related bone metastases, " Journal of Cellular Physiology, vol. 226, no. 3, pp. 780-784, 2011.
49. L. C. Hofbauer, S. Khosla, C. R. Dunstan, D. L. Lacey, W. J. Boyle, and B. L. Riggs, "The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption, " Journal of Bone and Mineral Research, vol. 15, no. 1, pp. 2-12, 2000.
50. R. Pacifici, "The immune system and bone, " Archives of Biochemistry and Biophysics, vol. 503, no. 1, pp. 41-53, 2010.
51. H. Takayanagi, K. Ogasawara, S. Hida et al., "T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-, " Nature, vol. 408, no. 6812, pp. 600-605, 2000.
52. K. Sato, T. Satoh, K. Shizume et al., "Prolonged decrease of serum calcium concentration by murine-interferon in hypercalcemic, human tumor (EC-GI)-bearing nude mice, " Cancer Research, vol. 52, no. 2, pp. 444-449, 1992.
53. Y. Gao, F. Grassi, M. R. Ryan et al., "IFN-stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation, " The Journal of Clinical Investigation, vol. 117, no. 1, pp. 122-132, 2007.
54. S. Cenci, G. Toraldo, M. N. Weitzmann et al., "Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-induced class II transactivator, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10405-10410, 2003.
55. S. Abbas and Y. Abu-Amer, "Dominant-negative IB facilitates apoptosis of osteoclasts by tumor necrosis factor-, " Journal of Biological Chemistry, vol. 278, no. 22, pp. 20077-20082, 2003.
56. R. Pacifici, "Estrogen deficiency, T cells and bone loss, " Cellular Immunology, vol. 252, no. 1-2, pp. 68-80, 2008.
57. S. Colucci, G. Brunetti, R. Rizzi et al., "T cells support osteoclastogenesis in an in vitromodel derived fromhumanmultiple myeloma bone disease: the role of theOPG/TRAIL interaction, " Blood, vol. 104, no. 12, pp. 3722-3730, 2004.
58. I. Roato, M. Grano, G. Brunetti et al., "Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement, " The FASEB Journal, vol. 19, no. 2, pp. 228-230, 2005.
59. I. Roato, E. Gorassini, L. Buffoni et al., "Spontaneous osteoclastogenesis is a predictive factor for bone metastases from nonsmall cell lung cancer, " Lung Cancer, vol. 61, no. 1, pp. 109-116, 2008.
60. P. M. Appasamy, "Biological and clinical implications of interleukin-7 and lymphopolesis, " Cytokines, Cellular and Molecular Therapy, vol. 5, no. 1, pp. 25-39, 1999.
61. A. E. Namen, S. Lupton, K. Hjerrild et al., "Stimulation of B-cell progenitors by cloned murine interleukin-7, " Nature, vol. 333, no. 6173, pp. 571-573, 1988.
62. M. A. A. Al-Rawi, K. Rmali, G. Watkins, R. E. Mansel, and W. G. Jiang, "Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer, " European Journal of Cancer, vol. 40, no. 4, pp. 494-502, 2004.
63. C. Miyaura, Y. Onoe, M. Inada et al., "Increased B-lymphopoiesis by interleukin 7 induces bone loss in micewith intact ovarian function: similarity to estrogen deficiency, " Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 17, pp. 9360-9365, 1997.
64. M. N. Weitzmann, C. Roggia, G. Toraldo, L. Weitzmann, and R. Pacifici, "Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency, " The Journal of Clinical Investigation, vol. 110, no. 11, pp. 1643-1650, 2002.
65. S.-K. Lee, J. F. Kalinowski, S. L. Jastrzebski, L. Puddington, and J. A. Lorenzo, "Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis, " Endocrinology, vol. 144, no. 8, pp. 3524-3531, 2003.
66. G. Toraldo, C. Roggia, W.-P. Qian, R. Pacific, and M. N. Weitzmann, "IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor B ligand and tumor necrosis factor from T cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 1, pp. 125-130, 2003.
67. N.Giuliani, S. Colla, R. Sala et al., "Humanmyeloma cells stimulate the receptor activator of nuclear factor-B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease, " Blood, vol. 100, no. 13, pp. 4615-4621, 2002.
68. I. Roato, G. Brunetti, E.Gorassini et al., "IL-7 up-regulates TNF-dependent osteoclastogenesis in patients affected by solid tumor, " PLoS ONE, vol. 1, article e124, 2006.
69. P. D'Amelio, A. Grimaldi, S. Di Bella et al., "Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis, " Bone, vol. 43, no. 1, pp. 92-100, 2008.
70. I. Roato, E. Gorassini, G. Brunetti et al., "IL-7 modulates osteoclastogenesis in patients affected by solid tumors, " Annals of the New York Academy of Sciences, vol. 1117, pp. 377-384, 2007.
71. I. Roato, D. Caldo, L. Godio et al., "Bone invading NSCLC cells produce IL-7: mice model and human histologic data, " BMC Cancer, vol. 10, article 12, 2010.
72. J. R. Kiesel, Z. S. Buchwald, and R. Aurora, "Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells, " The Journal of Immunology, vol. 182, no. 9, pp. 5477-5487, 2009.
73. R. Senthilkumar and H.-W. Lee, "CD137L-and RANKLmediated reverse signals inhibit osteoclastogenesis and T lymphocyte proliferation, " Immunobiology, vol. 214, no. 2, pp. 153-161, 2009.
74. M. Feuerer, M. Rocha, L. Bai et al., "Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients, " International Journal of Cancer, vol. 92, no. 1, pp. 96-105, 2001.
75. W. Tan, W. Zhang, A. Strasner et al., "Tumour-infiltrating regulatory T cells stimulate mammary cancermetastasis through RANKL-RANK signalling, " Nature, vol. 470, no. 7335, pp. 548-553, 2011.
76. S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell, "Transforming growth factor-and the immune response: implications for anticancer therapy, " Clinical Cancer Research, vol. 13, no. 18, pp. 5262-5270, 2007.
77. K. Schilbach, A. Geiselhart, and R. Handgretinger, "Induction of proliferation and augmented cytotoxicity of T lymphocytes by bisphosphonate clodronate, " Blood, vol. 97, no. 9, pp. 2917-2918, 2001.
78. K. Zhang, S. Kim, V. Cremasco et al., "CD8+ T cells regulate bone tumor burden independent of osteoclast resorption, " Cancer Research, vol. 71, no. 14, pp. 4799-4808, 2011.
79. S.-H. Yoon, Y. Lee, H.-J. Kim et al., "Lyn inhibits osteoclast differentiation by interfering with PLC1-mediated Ca2+ signaling, " FEBS Letters, vol. 583, no. 7, pp. 1164-1170, 2009.
80. V. Bronte, E. Apolloni, A. Cabrelle et al., "Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells, " Blood, vol. 96, no. 12, pp. 3838-3846, 2000.
81. D. I. Gabrilovich, M. P. Velders, E. M. Sotomayor, and W. M. Kast, "Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells, " Journal of Immunology, vol. 166, no. 9, pp. 5398-5406, 2001.
82. G. Gallina, L.Dolcetti, P. Serafini et al., "Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells, " The Journal of Clinical Investigation, vol. 116, no. 10, pp. 2777-2790, 2006.
83. S. Kusmartsev, S. Nagaraj, and D. I. Gabrilovich, "Tumorassociated CD8+ T cell tolerance induced by bone marrowderived immature myeloid cells, " The Journal of Immunology, vol. 175, no. 7, pp. 4583-4592, 2005.
84. B. Almand, J. I. Clark, E. Nikitina et al., "Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer, "The Journal of Immunology, vol. 166, no. 1, pp. 678-689, 2001.
85. W. Li, K. Wu, E. Zhao et al., "HMGB1 recruits myeloid derived suppressor cells to promote peritoneal dissemination of colon cancer after resection, " Biochemical and Biophysical Research Communications, vol. 436, no. 2, pp. 156-161, 2013.
86. S. Kusmartsev, Y. Nefedova, D. Yoder, and D. I. Gabrilovich, "Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species, " TheJournal of Immunology, vol. 172, no. 2, pp. 989-999, 2004.
87. Y. Liu, J. A. Van Ginderachter, L. Brys, P. De Baetselier, G. Raes, and A. B. Geldhof, "Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells, " The Journal of Immunology, vol. 170, no. 10, pp. 5064-5074, 2003.
88. A. Mazzoni, V. Bronte, A. Visintin et al., "Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism, " The Journal of Immunology, vol. 168, no. 2, pp. 689-695, 2002.
89. A. Sawant, J. Deshane, J. Jules et al., "Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer, " Cancer Research, vol. 73, no. 2, pp. 672-682, 2013.
90. S. Das, R. S. Samant, and L. A. Shevde, "Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis, "The Journal of Biological Chemistry, vol. 286, no. 11, pp. 9612-9622, 2011.
91. J. Zhuang, J. Zhang, S. T. Lwin et al., "Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells, " PLoS ONE, vol. 7, no. 11, Article ID e48871, 2012.
92. A.-H. Capietto, S. Kim, D. E. Sanford et al., "Down-regulation of PLC2-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer, " Journal of Experimental Medicine, vol. 210, no. 11, pp. 2257-2271, 2013.